查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983695

靜脈注射免疫球蛋白市場：按產品類型、患者類型、適應症、最終用戶和分銷管道分類的全球市場預測，2026-2032年

Intravenous Immunoglobulin Market by Product Type, Patient Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，靜脈注射免疫球蛋白市場價值將達到 143.5 億美元，到 2026 年將成長至 154.2 億美元，到 2032 年將達到 241.5 億美元，年複合成長率為 7.72%。

主要市場統計數據
基準年 2025 143.5億美元
預計年份：2026年 154.2億美元
預測年份 2032 241.5億美元
複合年成長率 (%) 7.72%

觀點對靜脈注射免疫球蛋白如何在不同的臨床環境和不斷變化的監管要求下支持現代免疫療法進行了清晰權威的說明。

靜脈注射免疫球蛋白在現代免疫療法中發揮核心作用，是多種臨床適應症的重要治療方法。臨床醫生依靠這些血漿衍生產品來調節自體免疫疾病、血液系統疾病、免疫力缺乏疾病以及某些神經系統疾病的免疫反應。在現代醫療保健中，靜脈注射免疫球蛋白因其作用機制廣泛且適用於住院、門診病人和專科治療等多種環境而備受重視，其產品系列完美地兼顧了臨床緊急治療和長期疾病管理。

製造技術的創新、臨床指南的完善以及監管機構對可追溯性的重視，正在重塑靜脈注射免疫球蛋白的供應鏈和治療應用。

靜脈注射免疫球蛋白領域正經歷著一場變革，其驅動力來自生產技術的進步、臨床實踐的改變以及監管機構對產品來源日益成長的關注。新的生產方法以及純化和製劑技術的改進降低了不利事件的發生率，延長了產品的保存期限，並提供了更穩定的液體製劑。這些都影響著醫院的用藥決策和門診給藥模式。同時，臨床醫師正基於不斷累積的真實世界數據，不斷完善適應症和給藥策略，使臨床指引與實際應用更加契合。

關稅變化對全球血漿採購、生產經濟性和免疫球蛋白療法採購韌性的連鎖反應。

關稅及相關貿易措施的實施可能會對嚴重依賴跨境血漿供應和國際生產網路的全球治療產業產生連鎖反應。影響原料、包裝材料或成品的關稅調整可能會給採購團隊和醫院藥房帶來額外的成本壓力，迫使他們重新評估其籌資策略以及與供應商和經銷商的合約結構。作為應對措施，企業可能會尋求在地化生產並實現供應商多元化，以降低對單一貿易體系的依賴。

對醫療保健機構、產品配方、患者人口統計特徵、分銷管道和臨床適應症等方面的准入趨勢進行全面細分分析。

詳細的市場細分揭示了臨床需求、製劑偏好和分銷管道趨勢的交匯點，從而塑造了產品的使用模式。最終使用者因素涵蓋居家照護、醫院和專科診所，其中醫院又可細分為私立和公立機構，專科診所則可細分為血液科、免疫科和神經科等科室。這些區分至關重要，因為不同的管理環境會影響管理物流、監測要求和合約方式。私立醫院和專科診所通常與公立醫院協商不同的報銷和採購條款，居家照護需要與護理服務部門協調，並進行低溫運輸配送。

影響美洲、歐洲、中東、非洲和亞太地區供應鏈韌性、監管嚴格程度和臨床引入模式的區域趨勢。

區域趨勢影響從捐贈血漿到患者的治療方法流程，每個宏觀區域都有其獨特的法規、物流和需求面因素。在美洲，完善的血漿採集基礎設施、臨床醫生對靜脈注射免疫球蛋白適應症的深刻理解以及先進的醫院環境支持了其廣泛應用，而區域支付方（保險公司）的政策和採購框架則影響著產品的選擇和合約方式。公立和私立醫療保健系統之間的差異、專科診所的作用以及門診輸液服務的密度都會影響全部區域治療方法的實施和報銷方式。

血漿採購、生產規模和臨床證據的策略性投資如何區分主要製造商和分銷合作夥伴。

產業相關人員正面臨一個複雜的環境，在這個環境中，規模、供應穩定性和合規性至關重要。主要企業正投資於上游工程，例如血漿採集、擴大分餾能力以及加強病原體去除和分析檢測，以提高產品的安全性和一致性。血漿採集網路與生產商之間的策略合作日益普遍，旨在確保原料的穩定供應並降低供應中斷的風險。同時，各企業正透過配方技術的進步、涵蓋多種適應症的廣泛產品系列以及附加價值服務（例如患者支持計劃和與輸液中心的合作）來實現差異化競爭。

為製造商和供應商提供切實可行的策略措施，以確保供應鏈安全、增強臨床實踐機會並最佳化銷售管道。

產業領導企業應採取多管齊下的策略，平衡供應韌性、與臨床機構的合作以及商業性彈性。加強與血漿採集網路的上游夥伴關係，並投資區域血漿分離能力，可以縮短前置作業時間，同時減輕貿易中斷和關稅的影響。同時，透過投資改進配方和分析技術來增強產品差異化，將有助於提高處方集採納率，並促進其在住院和門診病人環境中的應用。

一個嚴謹的混合方法研究框架，結合專家訪談、監管分析和供應鏈情境分析方法，以檢驗關鍵發現。

本研究途徑結合了多方面的證據基礎和系統檢驗，以確保獲得可靠的知識和可操作的見解。主要研究包括對血液科、免疫科和神經科的臨床醫生、公立和私立醫院的採購經理和藥屋主任以及血漿採集和分離機構的高級管理人員進行詳細訪談。這些對話提供了關於臨床實踐、合約趨勢和營運限制的詳細觀點，並用於檢驗從二手資訊中觀察到的趨勢。

整合不斷變化的臨床、運作和政策因素，這些因素決定了免疫球蛋白療法的可及性、安全性和治療價值。

靜脈注射免疫球蛋白仍然是治療多種免疫、血液和神經系統疾病的基石治療方法，但其研發、採購和交付環境正在迅速變化。儘管生產技術的進步和更嚴格的監管要求提高了產品品質和安全性，但供應鏈策略的轉變和區域生產能力的變化正在重塑免疫球蛋白的獲取途徑。臨床醫生、保險公司和醫療保健系統將越來越重視循證用藥、透明的來源資訊和可靠的採購管道，以確保治療的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：靜脈注射免疫球蛋白市場：依產品類型分類

  • 高純度免疫球蛋白
  • 正常免疫球蛋白
    • 液體
    • 冷凍乾燥

第9章：依病患類型分類的靜脈注射免疫球蛋白市場

  • 成人版
  • 老年人
  • 兒童

第10章：靜脈注射免疫球蛋白市場：依適應症分類

  • 自體免疫疾病
    • Guillain-Barré二氏症候群
    • 免疫性血小板缺乏紫斑症
    • 川崎病
  • 血液疾病
  • 免疫力缺乏
    • 原發性免疫力缺乏
    • 次發性免疫力缺乏
  • 神經系統疾病
    • 慢性脫髓鞘多發性神經炎
    • 多灶性運動神經病變

第11章 靜脈注射免疫球蛋白市場：依最終使用者分類

  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 血液科診所
    • 免疫診所
    • 神經科診所

第12章 靜脈注射免疫球蛋白市場：依通路分類

  • 直銷
  • 醫院藥房
  • 零售藥房
  • 批發商

第13章 靜脈注射免疫球蛋白市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 靜脈注射免疫球蛋白市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 靜脈注射免疫球蛋白市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國靜脈注射免疫球蛋白市場

第17章：中國靜脈注射免疫球蛋白市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Baxter International Inc.
  • Bio Products Laboratory Limited
  • Biotest AG
  • CSL Limited
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Option Care Health, Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market was valued at USD 14.35 billion in 2025 and is projected to grow to USD 15.42 billion in 2026, with a CAGR of 7.72%, reaching USD 24.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.35 billion
Estimated Year [2026] USD 15.42 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 7.72%

A clear, authoritative framing of how intravenous immunoglobulin underpins modern immunotherapy across diverse clinical settings and evolving regulatory expectations

Intravenous immunoglobulin occupies a central role in modern immunotherapy, serving as a critical therapeutic modality across a diverse set of clinical indications. Clinicians rely on these plasma-derived preparations to modulate immune responses in autoimmune, hematological, immunodeficiency, and selected neurological disorders. In contemporary practice, intravenous immunoglobulin is valued both for its broad mechanism of action and for its adaptability across inpatient, outpatient, and specialty care settings, making it a product class that intersects clinical urgency and long-term disease management.

Recent advances in manufacturing and quality control have elevated product consistency and safety profiles, while regulatory scrutiny and supply chain dynamics continue to shape access and utilization. The therapeutic landscape is being influenced by evolving clinical guidelines, greater emphasis on evidence-based use, and the integration of novel indications supported by emerging clinical data. As a result, stakeholders from clinicians to procurement leaders need nuanced insights into how clinical practice, manufacturing scale, and distribution channels interact to determine availability, therapeutic sequencing, and patient outcomes.

How manufacturing innovation, clinical guideline refinement, and regulatory emphasis on traceability are reshaping supply chains and therapeutic use of intravenous immunoglobulin

The intravenous immunoglobulin landscape is undergoing transformative shifts driven by advances in manufacturing, changing clinical practice, and heightened regulatory emphasis on product provenance. New manufacturing approaches and improvements in purification and formulation have reduced adverse event profiles and enabled longer shelf life and more stable liquid presentations, which in turn influence hospital formulary decisions and outpatient administration models. Concurrently, clinicians are refining indications and dosing strategies based on accumulating real-world evidence, prompting tighter alignment between clinical guidelines and utilization.

Supply chain resilience has become a strategic priority as plasma sourcing, donor recruitment, and international logistics face increasing scrutiny. This has spurred vertical integration, strategic partnerships between plasma suppliers and manufacturers, and investment in regional processing capacity. Regulatory agencies are emphasizing traceability and pathogen safety, and health systems are responding with more rigorous procurement standards and contingency planning. Collectively, these shifts are altering where and how intravenous immunoglobulin is produced, distributed, and administered, pressing industry participants to innovate across clinical, operational, and commercial domains.

The cascading effects of tariff changes on global plasma sourcing, production economics, and procurement resilience for immunoglobulin therapies

The imposition of tariffs and related trade measures can have a cascading influence on a global therapeutic class that depends heavily on cross-border plasma procurement and international manufacturing networks. Tariff adjustments affecting inputs, packaging materials, or finished products introduce additional cost pressure that procurement teams and hospital pharmacies must manage, and they can prompt manufacturers to re-evaluate sourcing strategies and contractual structures with suppliers and distributors. In response, firms may pursue localized production or diversify supplier bases to reduce exposure to a single trade regime.

Beyond immediate cost implications, tariffs influence contract negotiations and long-term strategic choices. They may accelerate moves toward regionalization of supply chains, encourage investments in domestic plasma collection and fractionation, or alter the economics of exporting finished product. Payers and hospital systems may shift purchasing patterns to prioritize products with more predictable landed costs, and manufacturers might adapt pricing structures or absorb a portion of tariff-related expenses to maintain competitive positioning. Ultimately, tariffs reshape the calculus around procurement resilience, supplier relationships, and regional manufacturing footprints in ways that require proactive commercial and operational adjustments.

Comprehensive segmentation analysis linking care settings, product formulations, patient demographics, distribution channels, and clinical indications to access dynamics

A granular view of segmentation reveals where clinical demand, formulation preferences, and channel dynamics intersect to shape utilization patterns. End-user considerations span home care, hospital, and specialty clinic settings, with hospitals further differentiated into private and public institutions and specialty clinics segmenting into hematology, immunology, and neurology practices. These distinctions matter because administration setting influences dosing logistics, monitoring requirements, and contracting approaches; private hospitals and specialty clinics often negotiate different reimbursement and procurement terms than public hospitals, and home care requires coordination with nursing services and cold-chain delivery.

Product-type segmentation distinguishes high purity immunoglobulin from standard preparations, and among standard products the formulation choice between liquid and lyophilized options affects storage, reconstitution workflow, and suitability for different care settings. Patient type segmentation identifies adult, geriatric, and pediatric populations, each with unique dosing paradigms and safety considerations that influence clinical protocols and payer coverage decisions. Distribution channel segmentation captures direct sales, hospital pharmacy supply, retail pharmacy dispensing, and wholesale distribution pathways, reflecting how procurement, inventory management, and service-level agreements vary across stakeholders. Indication-based segmentation encompasses autoimmune diseases, hematological conditions, immunodeficiency disorders, and neurological disorders, with autoimmune subcategories such as Guillain-Barre syndrome, immune thrombocytopenic purpura, and Kawasaki disease; hematological focus on hemolytic disease of the newborn; immunodeficiency subtypes including primary and secondary forms; and neurological emphasis on chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Integrating these segmentation lenses clarifies where clinical demand concentrates, how supply models must adapt, and which channels are most critical for timely patient access.

Regional dynamics driving supply chain resilience, regulatory rigor, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape how therapies move from donor plasma to patients, and each macro-region presents distinct regulatory, logistical, and demand-side factors. In the Americas, established plasma collection infrastructure, strong clinician familiarity with intravenous immunoglobulin indications, and advanced hospital settings support broad utilization, while regional payer policies and procurement frameworks influence product selection and contracting approaches. Differences between public and private systems, the role of specialized clinics, and the density of outpatient infusion services all affect how therapies are administered and reimbursed across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with national pricing and reimbursement variability. Several countries in this region emphasize stringent traceability and pathogen safety requirements, and both public procurement mechanisms and private specialty networks play roles in access. Investment in regional fractionation capacity and growing attention to supply security are shaping strategic priorities. In Asia-Pacific, rapid healthcare infrastructure expansion, rising clinical adoption across tertiary centers, and increasing investment in plasma collection capacity are notable. However, challenges persist related to distribution logistics, cold-chain reliability, and alignment between clinical guideline adoption and payer coverage. Taken together, regional differences influence manufacturer strategy, clinical adoption timelines, and the design of distribution partnerships to ensure consistent patient access.

How strategic investments in plasma sourcing, manufacturing scale, and clinical evidence are differentiating leading producers and distribution partners

Key industry participants are navigating a complex environment that rewards scale, supply security, and regulatory compliance. Leading firms are investing in upstream plasma sourcing, expanding fractionation capacity, and enhancing pathogen reduction and analytical testing to strengthen product safety and consistency. Strategic alliances between plasma collection networks and manufacturers are increasingly common, aiming to secure raw material streams and reduce exposure to supply disruptions. At the same time, companies are differentiating through formulation advances, portfolio breadth across indications, and value-added services such as patient support programs and infusion center partnerships.

Competitive dynamics also reflect varied go-to-market models: some organizations emphasize direct sales to large hospital systems and integrated health networks, while others prioritize distribution via hospital pharmacies, retail channels, or wholesale partners to reach a broader clinical base. Mergers, targeted acquisitions, and technology partnerships that improve manufacturing yield or reduce cycle time are shaping the competitive map. Additionally, a focus on evidence generation, real-world outcomes studies, and targeted clinical programs is enhancing payer conversations and supporting label expansions or guideline inclusion for new and established indications.

Practical strategic moves for manufacturers and suppliers to secure supply chains, strengthen clinical access, and optimize commercial channel alignment

Industry leaders should adopt a multidimensional strategy that balances supply resilience, clinical engagement, and commercial agility. Strengthening upstream partnerships with plasma collection networks and investing in regional fractionation capabilities will reduce exposure to trade disruptions and tariffs while improving lead times. Simultaneously, enhancing product differentiation through formulation improvements and investment in analytical methods will support formulary positioning and facilitate adoption across inpatient and outpatient settings.

Commercially, organizations should tailor channel strategies to account for differences in direct hospital procurement, hospital pharmacy distribution, retail dispensing, and wholesale networks, and align contracting and value propositions with the specific needs of private versus public institutions and specialty clinics. Clinically, partnering with key opinion leaders across hematology, immunology, and neurology to build robust real-world evidence can accelerate guideline adoption and clarify appropriate utilization across adult, geriatric, and pediatric populations. Finally, firms should implement dynamic pricing and risk-sharing mechanisms that address payer concerns while preserving access, and maintain transparent communication with regulators and health systems to anticipate policy shifts and ensure uninterrupted patient care.

A rigorous mixed-methods research framework blending expert interviews, regulatory analysis, and supply-chain scenario techniques to validate key insights

The research approach combined a multi-source evidence base with structured validation to ensure robust findings and actionable insights. Primary research included in-depth interviews with clinicians across hematology, immunology, and neurology specialties, procurement leaders from private and public hospitals, pharmacy directors, and senior executives in plasma collection and fractionation organizations. These conversations provided granular perspectives on clinical practice, contracting dynamics, and operational constraints, and were used to validate trends observed in secondary sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, manufacturing quality standards, and publicly available filings and technical materials. Analytical methods integrated qualitative synthesis of stakeholder interviews with process mapping of supply chains, scenario analysis of trade and tariff impacts, and comparative review of formulation and distribution models. Quality assurance steps included cross-validation of interview findings against regulatory and clinical literature, internal expert review, and methodological transparency about data limitations and potential biases. This layered approach ensured the report's conclusions rested on convergent evidence and practitioner-informed interpretation.

Synthesis of the evolving clinical, operational, and policy drivers that will determine access, safety, and therapeutic value for immunoglobulin therapies

Intravenous immunoglobulin remains a cornerstone therapy across a range of immunologic, hematologic, and neurologic indications, but the environment in which it is developed, sourced, and delivered is evolving rapidly. Manufacturing advances and tighter regulatory expectations have improved product quality and safety, while shifts in supply chain strategy and regional capacity are reshaping access dynamics. Clinicians, payers, and health systems will increasingly demand evidence-aligned use, transparent provenance, and resilient procurement pathways to ensure continuity of care.

Looking ahead, stakeholders who proactively invest in secure plasma sourcing, flexible manufacturing footprints, and rigorous clinical evidence generation will be best positioned to navigate tariff pressures, distribution complexities, and shifting care models. Cross-sector collaboration among manufacturers, plasma collection networks, clinicians, and payers will be essential to sustain availability and to optimize therapeutic value for patients across diverse care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intravenous Immunoglobulin Market, by Product Type

  • 8.1. High Purity Immunoglobulin
  • 8.2. Normal Immunoglobulin
    • 8.2.1. Liquid
    • 8.2.2. Lyophilized

9. Intravenous Immunoglobulin Market, by Patient Type

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Intravenous Immunoglobulin Market, by Indication

  • 10.1. Autoimmune Diseases
    • 10.1.1. Guillain-Barre Syndrome
    • 10.1.2. Immune Thrombocytopenic Purpura
    • 10.1.3. Kawasaki Disease
  • 10.2. Hematological Conditions
  • 10.3. Immunodeficiency Disorders
    • 10.3.1. Primary Immunodeficiency
    • 10.3.2. Secondary Immunodeficiency
  • 10.4. Neurological Disorders
    • 10.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.4.2. Multifocal Motor Neuropathy

11. Intravenous Immunoglobulin Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
    • 11.2.1. Private Hospital
    • 11.2.2. Public Hospital
  • 11.3. Specialty Clinic
    • 11.3.1. Hematology Clinic
    • 11.3.2. Immunology Clinic
    • 11.3.3. Neurology Clinic

12. Intravenous Immunoglobulin Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacy
  • 12.3. Retail Pharmacy
  • 12.4. Wholesale Distributor

13. Intravenous Immunoglobulin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intravenous Immunoglobulin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intravenous Immunoglobulin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Intravenous Immunoglobulin Market

17. China Intravenous Immunoglobulin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Baxter International Inc.
  • 18.6. Bio Products Laboratory Limited
  • 18.7. Biotest AG
  • 18.8. CSL Limited
  • 18.9. Grifols, S.A.
  • 18.10. Johnson & Johnson Services, Inc.
  • 18.11. Kedrion S.p.A.
  • 18.12. LFB S.A.
  • 18.13. Octapharma AG
  • 18.14. Option Care Health, Inc.
  • 18.15. Shanghai RAAS Blood Products Co., Ltd.
  • 18.16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 216. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 224. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 252. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 259. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 260. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 264. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 271. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 272. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)